Although the efficacy of therapeutic granulocyte transfusions as treatment for progressive infections in severely neutropenic patients is supported by the medical literature, this form of therapy is not widely accepted because it has been extremely difficult to transfuse an adequate dose of compatible granulocytes. Recently, the possibility has been raised to greatly increase the number of granulocytes collected by stimulating normal donors with recombinant granulocyte colony-stimulating factor. Accordingly, it is reasonable to reassess the possible role for granulocyte transfusions as therapy for progressive bacterial, yeast, and fungal infections.